Advertisement

Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia

  • Gianluca AbbatiEmail author
  • Federica Incerti
  • Chiara Boarini
  • Francesca Pileri
  • Davide Bocchi
  • Paolo Ventura
  • Elena Buzzetti
  • Antonello Pietrangelo
IM - ORIGINAL
  • 73 Downloads

Abstract

Iron deficiency anemia (IDA) is one of the most common complications of inflammatory bowel disease (IBD). We planned a prospective study to address tolerability and efficacy of sucrosomial iron, a new oral formulation of ferric pyrophosphate, in IBD patients. Thirty patients with a confirmed diagnosis of Crohn’s Disease (CD) or ulcerative colitis (UC) and mild IDA were enrolled. Patients with severe IBD were excluded. All patients underwent 12 weeks of oral treatment with 30 mg/day of sucrosomial iron. Treatment compliance and adverse events were investigated every 4 weeks. Iron status, hematological parameters and IBD activity scores were determined at baseline and at the end of treatment, as well as serum hepcidin and non-transferrin bound iron (NTBI) levels. Twenty-four (80%) patients took more than 90% of the prescribed regimen. Forty-four adverse events (AEs) were recorded, but none of them is considered certainly or probably related to the study treatment. Interestingly, only eleven gastrointestinal events were recorded in 9 (30%) patients. At the end of treatment, all iron parameters improved significantly and Hb increased in 86% of patients (from 11.67 to 12.37 g/dl, p = 0.001). Serum hepcidin showed a significant increase in 79% of patients and became positively correlated with C-reactive protein (CRP) at the end of the study, while NTBI remained below the detection threshold after iron supplementation. The IBD activity scores improved in both CD and UC. This pilot interventional study supports the therapeutic use of sucrosomial iron in IBD and paves the way for future studies in larger or more difficult IBD populations.

Keywords

IBD Iron Sucrosomial Anemia Hepcidin 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Testa A, Rispo A, Romano M, Riegler G, Selvaggi F, Bottiglieri E, Martorano M, Rea M, Gravina A, Nardone OM, Patturelli M, Pellino G, Miranda A, Caporaso N, Castiglione F (2016) The burden of anaemia in patients with inflammatory bowel diseases. Dig Liver Dis 48:267–270.  https://doi.org/10.1016/j.dld.2015.10.012 CrossRefPubMedGoogle Scholar
  2. 2.
    Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergamaschi G, Koutroubakis I, Lindgren S, Morena Fde L, Moum B, Vavricka SR, Schroder O, Herrmann E, Blumenstein I (2014) Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis 20:936–945.  https://doi.org/10.1097/01.MIB.0000442728.74340.fd CrossRefPubMedGoogle Scholar
  3. 3.
    Bergamaschi G, Di Sabatino A, Albertini R, Ardizzone S, Biancheri P, Bonetti E, Cassinotti A, Cazzola P, Markopoulos K, Massari A, Rosti V, Porro GB, Corazza GR (2010) Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica 95:199–205.  https://doi.org/10.3324/haematol.2009.009985 CrossRefPubMedGoogle Scholar
  4. 4.
    Kulnigg S, Gasche C (2006) Systematic review: managing anaemia in Crohn’s disease. Aliment Pharmacol Ther 24:1507–1523.  https://doi.org/10.1111/j.1365-2036.2006.03146.x CrossRefPubMedGoogle Scholar
  5. 5.
    Zimmermann MB, Hurrell RF (2007) Nutritional iron deficiency. Lancet 370:511–520.  https://doi.org/10.1016/S0140-6736(07)61235-5 CrossRefPubMedGoogle Scholar
  6. 6.
    Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, Gomollon F, Hjortswang H, Koutroubakis I, Kulnigg S, Oldenburg B, Rampton D, Schroeder O, Stein J, Travis S, Van Assche G (2007) Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 13:1545–1553.  https://doi.org/10.1002/ibd.20285 CrossRefPubMedGoogle Scholar
  7. 7.
    Theurl I, Schroll A, Nairz M, Seifert M, Theurl M, Sonnweber T, Kulaksiz H, Weiss G (2011) Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica 96:1761–1769.  https://doi.org/10.3324/haematol.2011.048926 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dignass AU, Gasche C, Bettenworth D, Birgegard G, Danese S, Gisbert JP, Gomollon F, Iqbal T, Katsanos K, Koutroubakis I, Magro F, Savoye G, Stein J, Vavricka S, Cs European, Colitis O (2015) European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 9:211–222.  https://doi.org/10.1093/ecco-jcc/jju009 CrossRefPubMedGoogle Scholar
  9. 9.
    Kaitha S, Bashir M, Ali T (2015) Iron deficiency anemia in inflammatory bowel disease. World J Gastrointest Pathophysiol 6:62–72.  https://doi.org/10.4291/wjgp.v6.i3.62 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lee TW, Kolber MR, Fedorak RN, van Zanten SV (2012) Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis 6:267–275.  https://doi.org/10.1016/j.crohns.2011.09.010 CrossRefPubMedGoogle Scholar
  11. 11.
    de Silva AD, Tsironi E, Feakins RM, Rampton DS (2005) Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther 22:1097–1105.  https://doi.org/10.1111/j.1365-2036.2005.02700.x CrossRefPubMedGoogle Scholar
  12. 12.
    Grisham MB (1994) Oxidants and free radicals in inflammatory bowel disease. Lancet 344:859–861CrossRefGoogle Scholar
  13. 13.
    Erichsen K, Ulvik RJ, Grimstad T, Berstad A, Berge RK, Hausken T (2005) Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease. Aliment Pharmacol Ther 22:831–838.  https://doi.org/10.1111/j.1365-2036.2005.02652.x CrossRefPubMedGoogle Scholar
  14. 14.
    Lund EK, Wharf SG, Fairweather-Tait SJ, Johnson IT (1999) Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr 69:250–255.  https://doi.org/10.1093/ajcn/69.2.250 CrossRefPubMedGoogle Scholar
  15. 15.
    Seril DN, Liao J, Ho KL, Warsi A, Yang CS, Yang GY (2002) Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig Dis Sci 47:1266–1278CrossRefGoogle Scholar
  16. 16.
    Zimmermann MB, Chassard C, Rohner F, N’Goran EK, Nindjin C, Dostal A, Utzinger J, Ghattas H, Lacroix C, Hurrell RF (2010) The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d’Ivoire. Am J Clin Nutr 92:1406–1415.  https://doi.org/10.3945/ajcn.110.004564 CrossRefPubMedGoogle Scholar
  17. 17.
    Simao AMS, Bolean M, Cury TAC, Stabeli RG, Itri R, Ciancaglini P (2015) Liposomal systems as carriers for bioactive compounds. Biophys Rev 7:391–397.  https://doi.org/10.1007/s12551-015-0180-8 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Brilli E, Romano A, Fabiano A, Zambito Y, Di Raimondo F, Tarantino G (2016) Sucrosomial technology is able to promote ferric iron absorption: pre-clinical and clinical evidences. Blood 128:3618Google Scholar
  19. 19.
    Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B (2015) Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant 30:645–652.  https://doi.org/10.1093/ndt/gfu357 CrossRefPubMedGoogle Scholar
  20. 20.
    Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P, Ecco (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11:3–25.  https://doi.org/10.1093/ecco-jcc/jjw168 CrossRefPubMedGoogle Scholar
  21. 21.
    Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagorowicz E, Raine T, Harbord M, Rieder F, Cs European, Colitis O (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 11:649–670.  https://doi.org/10.1093/ecco-jcc/jjx008 CrossRefPubMedGoogle Scholar
  22. 22.
    Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298:82–86CrossRefGoogle Scholar
  23. 23.
    Best WR, Becktel JM, Singleton JW, Kern F Jr (1976) Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 70:439–444PubMedGoogle Scholar
  24. 24.
    Guidelines for Good Clinical Practice E6(R1), (1996) International Conference on harmonization of technical requirementsGoogle Scholar
  25. 25.
    Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P (2005) LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 18:277–287.  https://doi.org/10.1016/j.beha.2004.10.003 CrossRefPubMedGoogle Scholar
  26. 26.
    Zipperer E, Post JG, Herkert M, Kundgen A, Fox F, Haas R, Gattermann N, Germing U (2013) Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome. Ann Hematol 92:1617–1623.  https://doi.org/10.1007/s00277-013-1839-5 CrossRefPubMedGoogle Scholar
  27. 27.
    Zanninelli G, Breuer W, Cabantchik ZI (2009) Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients. Br J Haematol 147:744–751.  https://doi.org/10.1111/j.1365-2141.2009.07907.x CrossRefPubMedGoogle Scholar
  28. 28.
    Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, Stallmach A, Buning C, Group AS (2016) Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. Aliment Pharmacol Ther 44:259–270.  https://doi.org/10.1111/apt.13665 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J (2005) Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 100:2503–2509.  https://doi.org/10.1111/j.1572-0241.2005.00250.x CrossRefPubMedGoogle Scholar
  30. 30.
    Pietrangelo A, Trautwein C (2004) Mechanisms of disease: the role of hepcidin in iron homeostasis—implications for hemochromatosis and other disorders. Nat Clin Pract Gastroenterol Hepatol 1:39–45.  https://doi.org/10.1038/ncpgasthep0019 CrossRefPubMedGoogle Scholar
  31. 31.
    Ganz T, Nemeth E (2012) Hepcidin and iron homeostasis. Biochim Biophys Acta 1823:1434–1443.  https://doi.org/10.1016/j.bbamcr.2012.01.014 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Bergamaschi G, Di Sabatino A, Albertini R, Costanzo F, Guerci M, Masotti M, Pasini A, Massari A, Campostrini N, Corbella M, Girelli D, Corazza GR (2013) Serum hepcidin in inflammatory bowel diseases: biological and clinical significance. Inflamm Bowel Dis 19:2166–2172.  https://doi.org/10.1097/MIB.0b013e31829a6e43 CrossRefPubMedGoogle Scholar
  33. 33.
    Mecklenburg I, Reznik D, Fasler-Kan E, Drewe J, Beglinger C, Hruz P, Swiss IBDCSG (2014) Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease. J Crohns Colitis 8:1392–1397.  https://doi.org/10.1016/j.crohns.2014.04.008 CrossRefPubMedGoogle Scholar
  34. 34.
    Dresow B, Petersen D, Fischer R, Nielsen P (2008) Non-transferrin-bound iron in plasma following administration of oral iron drugs. Biometals 21:273–276.  https://doi.org/10.1007/s10534-007-9116-5 CrossRefPubMedGoogle Scholar
  35. 35.
    Schumann K, Kroll S, Weiss G, Frank J, Biesalski HK, Daniel H, Friel J, Solomons NW (2005) Monitoring of hematological, inflammatory and oxidative reactions to acute oral iron exposure in human volunteers: preliminary screening for selection of potentially-responsive biomarkers. Toxicology 212:10–23.  https://doi.org/10.1016/j.tox.2005.03.014 CrossRefPubMedGoogle Scholar
  36. 36.
    Erichsen K, Milde AM, Arslan G, Helgeland L, Gudbrandsen OA, Ulvik RJ, Berge RK, Hausken T, Berstad A (2005) Low-dose oral ferrous fumarate aggravated intestinal inflammation in rats with DSS-induced colitis. Inflamm Bowel Dis 11:744–748CrossRefGoogle Scholar
  37. 37.
    Tarantino G, Brilli E, Zambito Y, Giordano G, Equitani F (2015) Sucrosomial Iron®: a new highly bioavaible oral iron supplement. Blood 126:4561Google Scholar

Copyright information

© Società Italiana di Medicina Interna 2018

Authors and Affiliations

  • Gianluca Abbati
    • 1
    Email author
  • Federica Incerti
    • 1
  • Chiara Boarini
    • 1
  • Francesca Pileri
    • 1
  • Davide Bocchi
    • 1
  • Paolo Ventura
    • 1
  • Elena Buzzetti
    • 1
  • Antonello Pietrangelo
    • 1
  1. 1.Division of Internal Medicine 2 and Center for HemochromatosisUniversity of Modena and Reggio EmiliaModenaItaly

Personalised recommendations